@Article{,
AUTHOR = {Kavitha Ramachandran, Mark S. Soloway, Rakesh Singal, Murugesan Manoharan},
TITLE = {The emerging role of epigenetics in urological cancers},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {14},
YEAR = {2007},
NUMBER = {3},
PAGES = {3535--3541},
URL = {http://www.techscience.com/CJU/v14n3/62399},
ISSN = {1488-5581},
ABSTRACT = {DNA methylation and histone modifications constitute
the common epigenetic modifications in vertebrate
genomes. The epigenetic changes are early event in the
cancer development and are reversible. Over the last
decade, the field of epigenetics has made considerable
progress both in the diagnosis and treatment of variety of
malignancies. Novel epigenetic markers are being studied,
which have the potential as sensitive diagnostic and
prognostic markers. DNA methylation has been identified
as a powerful diagnostic tool in classification, detection
and risk assessment of cancers. As DNA methylation is
reversible, inhibitors of DNA methyl transferases and
histone deacteylases have been designed for use in
treatment of a variety of urological malignancies. Variety
of drugs targeting epigenetic changes are being studied,
which can be effective individually or in combination with
other conventional drugs used in cancer therapy. The
emerging area of epigenetic therapy holds great promise
for novel chemotherapeutic and chemoprevention
approaches against cancer.},
DOI = {}
}